Related Experiment Video

Updated: Jun 7, 2025

Screening and Identification of Small Peptides Targeting Fibroblast Growth Factor Receptor2 using a Phage Display Peptide Library
07:32

Screening and Identification of Small Peptides Targeting Fibroblast Growth Factor Receptor2 using a Phage Display Peptide Library

Published on: September 30, 2019

7.6K

Fibroblast growth factor receptor inhibitor-induced hyperphosphatemia: Lessons for the nephrologist

Rose Mary Attieh, Pratap Upadrista, Anna T Levy

    Clinical Nephrology
    |November 19, 2024
    PubMed
    Abstract

    Insights

    Fibroblast growth factor receptor inhibitors (FGFRi) commonly cause hyperphosphatemia in cancer patients. This study found a high incidence of hyperphosphatemia, emphasizing the need for collaborative management between nephrologists and oncologists.

    Area of Science:

    • Oncology
    • Nephrology
    • Pharmacology

    Background:

    • Fibroblast growth factor receptor inhibitors (FGFRi) represent a novel class of targeted cancer therapies.
    • These drugs show promise for advanced biliary tract cancers and metastatic urothelial tumors.
    • Hyperphosphatemia is a frequent adverse effect associated with FGFRi treatment.

    Purpose of the Study:

    • To investigate the incidence and clinical characteristics of hyperphosphatemia in patients receiving FGFRi.
    • To compare real-world data with findings from clinical trials and the FDA Adverse Event Reporting System.
    • To highlight the importance of multidisciplinary care in managing FGFRi-induced hyperphosphatemia.

    Main Methods:

    • Retrospective analysis of patients treated with FGFRi at Northwell Health.
    • Comparison of observed hyperphosphatemia rates and characteristics against published clinical trial data.
    • Review of the FDA Adverse Event Reporting System (FAERS) database for FGFRi-related events.

    Main Results:

    • A high incidence of hyperphosphatemia (94%) was observed in the study cohort, predominantly Grade 2.
    • The time to onset of hyperphosphatemia was longer than reported in clinical trials.
    • Patients treated with erdafitinib exhibited a higher incidence and grade of hyperphosphatemia than anticipated.

    Conclusions:

    • Close collaboration between nephrologists and oncologists is essential for optimizing FGFRi therapy and managing side effects.
    • Further research is needed to establish refined management strategies for FGFRi-induced hyperphosphatemia.
    • Understanding the clinical implications of hyperphosphatemia is crucial for improving patient outcomes.

    More Related Videos

    Assessing Cellular Target Engagement by SHP2 PTPN11 Phosphatase Inhibitors08:45

    Assessing Cellular Target Engagement by SHP2 PTPN11 Phosphatase Inhibitors

    Published on: July 17, 2020

    6.2K
    An Automated Radiosynthesis of [68Ga]Ga-FAPI-46 for Routine Clinical Use10:33

    An Automated Radiosynthesis of [68Ga]Ga-FAPI-46 for Routine Clinical Use

    Published on: May 24, 2024

    716

    Related Concept Videos

    Renal Failure: Dose Adjustments01:11

    Renal Failure: Dose Adjustments

    In patients with renal impairment, drugs undergo significant changes in their pharmacokinetics, which require dosage adjustments to ensure safe and effective therapy.
    Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
    However, dosage adjustments...
    67
    Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

    Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

    Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
    TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
    141
    Roles of Electrolytes: Calcium and Phosphate01:27

    Roles of Electrolytes: Calcium and Phosphate

    Calcium and phosphate are essential electrolytes in the human body, with calcium being the most abundant mineral. Around 99% of the body's calcium is stored in the skeleton and teeth, forming a crystal lattice of mineral salts in combination with phosphates. Calcium plays crucial roles in various bodily functions such as blood clotting, neurotransmitter release, muscle tone maintenance, and nervous and muscle tissue excitability.
    The calcium concentration in blood plasma is primarily...
    170
    Transducer Mechanism: Enzyme-Linked Receptors01:27

    Transducer Mechanism: Enzyme-Linked Receptors

    Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
    Major types that are helpful drug targets include:
    2.4K
    Protein Kinases and Phosphatases02:54

    Protein Kinases and Phosphatases

    Proteins undergo chemical modifications that trigger changes in the charge, structure, and conformation of the proteins. Phosphorylation, acetylation, glycosylation, nitrosylation, ubiquitination, lipidation, methylation, and proteolysis are various protein modifications that regulate protein activity. Such modifications are usually enzyme-driven.
    Protein kinases
    Many proteins in the cell are regulated by phosphorylation, the addition of a phosphate group. A family of enzymes called kinases...
    13.1K
    Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors01:28

    Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors

    Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
    Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
    129